Adult patients (≥18 years) with confirmed cutaneous T-cell lymphoma evaluated at Hospital México between 2019 and 2025 will be retrospectively analyzed using EDUS records to describe their epidemiological profile, clinical characteristics, treatments, and outcomes.
This retrospective observational study will analyze adult patients (≥18 years) with a confirmed diagnosis of cutaneous T-cell lymphoma evaluated in the Dermatology Service of Hospital México between January 2019 and December 2025. Data will be obtained from electronic medical records (EDUS), including sociodemographic characteristics, clinical presentation, histopathological and immunohistochemical findings, disease staging, treatment modalities, and clinical outcomes. Patients must have at least one documented dermatological evaluation and have received treatment, including skin-directed therapies and/or systemic therapies. Records that are incomplete, inconsistent, or lack histopathological confirmation will be excluded. The study aims to characterize local epidemiological and therapeutic patterns and describe clinical outcomes using descriptive statistical analysis, providing updated real-world evidence to support clinical decision-making and optimize management strategies for cutaneous T-cell lymphoma in a national referral center.
Study Type
OBSERVATIONAL
Enrollment
350
Hospital México
San José, Uruca, Costa Rica
Characterize the epidemiology
Characterize the epidemiology of patients diagnosed with cutaneous T-cell lymphoma evaluated in the Dermatology Service of Hospital México.
Time frame: 2019-2025
Characterize the therapeutic management
Characterize the therapeutic management of patients diagnosed with cutaneous T-cell lymphoma evaluated in the Dermatology Service of Hospital México
Time frame: 2019-2025.
Describe the sociodemographic/epidemiological characteristics
To describe the sociodemographic and epidemiological characteristics of patients diagnosed with cutaneous T-cell lymphoma evaluated in the Dermatology Service of Hospital México during the period from 2019 to 2025.
Time frame: 2019-2025
Classify the clinical manifestations/clinical subtypes
Classify the clinical manifestations and clinical subtypes of cutaneous T-cell lymphoma present in the studied population.
Time frame: 2019-2025
Identify the histopathological/ immunohistochemical findings
To identify the histopathological and immunohistochemical findings associated with cutaneous T-cell lymphoma in the included patients.
Time frame: 2019-2025
Analyze the therapeutic management modalities.
Analyze the therapeutic management modalities used, including skin-directed therapies and their outcomes.
Time frame: 2019-2025
identify the clinical stage at the time of diagnosis
identify the clinical stage of the disease at the time of diagnosis according to the TNMB staging system.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 2019-2025
Evaluation of imaging studies and laboratory.
Evaluate imaging studies and laboratory findings of patients with cutaneous T-cell lymphoma during the follow-up period.
Time frame: 2019-2025
Evaluation of clinical course and outcomes.
Evaluation of clinical course and outcomes of patients with cutaneous T-cell lymphoma during the follow-up period.
Time frame: 2019-2025